|
|
|
| Physician + Biotech Builder with Tome Biosciences' Rahul Kakkar, M.D. | Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician—work he continues even as he builds Tome Biosciences, where he serves as President & CEO. On Business of Biotech, Dr. Kakkar shares how his work as a physician informs his leadership, biopharma’s bad rap, and a whole lot more. |
|
|
|
|
On this episode of the Business of Biotech, we'll dive into how the MRI tackles health problems that challenge some of the world's most vulnerable populations. |
|
|
| Emerging Vaccine Technologies | Article | FUJIFILM Diosynth Biotechnologies | Rapidly shifting modalities require broad CDMO expertise and capacity, and commercializing recombinant vector vaccines requires a skill set that differs from protein or peptide based approaches. |
|
|
|
|
| Accelerate And De-Risk Bioconjugate Drug Development | Article | By Elisabeth Engelsberger, Ph.D., and Raphael Frey, Ph.D., Lonza | With a growing interest in developing new and improved bioconjugate drugs, explore an “innovation through collaboration” approach that can facilitate access to next-generation conjugation technologies. |
|
|
| Optimizing CDMO Technical Transfer | Article | By Eleonora Bellissimi, Hue Rose Pham, and Paul Magreta, Grifols | Learn how a CDMO helps biopharma organizations predict and mediate technical transfer risks before they become costly, time-consuming problems. |
|
|
|
|
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
